Melanoma Skin Cancer Diagnostic Testing Market

Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.
Melanoma Skin Cancer Diagnostic Testing Market contains market size and forecasts of Melanoma Skin Cancer Diagnostic Testing in Global, including the following market information:
Global Melanoma Skin Cancer Diagnostic Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Melanoma Skin Cancer Diagnostic Testing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biopsy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Melanoma Skin Cancer Diagnostic Testing include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Melanoma Skin Cancer Diagnostic Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Melanoma Skin Cancer Diagnostic Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Melanoma Skin Cancer Diagnostic Testing Market Segment Percentages, by Type, 2021 (%)
Biopsy
Imaging
Others
Global Melanoma Skin Cancer Diagnostic Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Melanoma Skin Cancer Diagnostic Testing Market Segment Percentages, by Application, 2021 (%)
Hospitals
Dermatology Clinics
Diagnostic Laboratories
Others
Global Melanoma Skin Cancer Diagnostic Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Melanoma Skin Cancer Diagnostic Testing Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Melanoma Skin Cancer Diagnostic Testing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Melanoma Skin Cancer Diagnostic Testing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics